HK inno.N Corporation

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301

Phase 3

Completed

Conditions: Parenteral Nutrition

Interventions: Drug: IN-C006 Peri inj.
Drug: RPN301

First Posted Date: 2022-04-20

Last Posted Date: 2023-09-28

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 59

Registration Number: NCT05337228

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Inj. Compared With RCN301

Phase 3

Completed

Conditions: Parenteral Nutrition

Interventions: Drug: IN-C006 inj.
Drug: RCN301

First Posted Date: 2022-03-28

Last Posted Date: 2023-09-28

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 60

Registration Number: NCT05299099

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Study to Confirm the Safety and Efficacy of Tegoprazan in Patients With Healed Erosive Reflux Disease

Phase 4

Completed

Conditions: Erosive Reflux Disease

Interventions: Drug: Tegoprazan 50mg QD
Drug: Lansoprazole 30mg QD

First Posted Date: 2022-03-04

Last Posted Date: 2022-07-29

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 218

Registration Number: NCT05267743

Locations: 🇰🇷
Wonkwang University Hospital, Iksan, Muwang-ro 895, Korea, Republic of

A Bioequivalence Study Between Telmione 80 mg and Micardis 80 mg in Healthy Adult Volunteers

Phase 1

Conditions: Hypertension

Interventions: Drug: Telminone 80 mg

First Posted Date: 2022-02-03

Last Posted Date: 2022-03-02

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 46

Registration Number: NCT05223101

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of

Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)

Phase 1

Conditions: COVID-19

Interventions: Biological: IN-B009 (Low-dose)
Biological: IN-B009 (High-dose)

First Posted Date: 2021-11-09

Last Posted Date: 2021-11-09

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 40

Registration Number: NCT05113849

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Chungbuk National University Hospital, Chungju, Korea, Republic of
🇰🇷
Jeonbuk National University Hospital, Jeonju, Korea, Republic of

A Bioequivalence Study Between Telmione Plus 80/12.5mg and Micardis Plus 80/12.5 mg in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Telmione plus 80/12.5mg
Drug: Micardis plus 80/12.5mg

First Posted Date: 2021-09-10

Last Posted Date: 2022-02-16

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 46

Registration Number: NCT05040880

Locations: 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of

A Study to Investigate the Effect of Food on the Pharmacokinetics of IN-A002 Capsule in Healthy Male Subjects

Phase 1

Conditions: Healthy

Interventions: Drug: IN-A002(IN-115314) capsule

First Posted Date: 2021-08-25

Last Posted Date: 2021-08-25

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 12

Registration Number: NCT05019755

Locations: 🇰🇷
Seoul National University Hospital, Dept. of Clinical Pharmacology, Seoul, Korea, Republic of

Evaluation of the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 and IN-A001 in Healthy Caucasians

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: IN-A001 Y mg
Drug: IN-C005 X mg
Drug: IN-C005 Y mg
Drug: IN-C005 Z mg

First Posted Date: 2021-08-13

Last Posted Date: 2022-05-16

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 20

Registration Number: NCT05005065

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Jongro Gu, Korea, Republic of
🇰🇷
Seoul National University Hopsital, Seoul, Korea, Republic of

Study to Evaluate the Safety, Efficacy of Tegoprazan for the Prevention of PUD in Patients on Treatment With NSAIDs

Phase 3

Recruiting

Conditions: Preventive Peptic Ulcer

Interventions: Drug: Tegoprazan 25 mg
Drug: Lansoprazole 15 mg

First Posted Date: 2021-04-12

Last Posted Date: 2023-07-14

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 390

Registration Number: NCT04840550

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷
The catholic univ. of Korea Eunpyeong ST. Mari's hospital, Seoul, Korea, Republic of

Study to Evaluate Oral Mucosa Absorption of IN-C004 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: IN-C004

First Posted Date: 2020-12-04

Last Posted Date: 2021-01-29

Lead Sponsor: HK inno.N Corporation

Target Recruit Count: 6

Registration Number: NCT04654065

Locations: 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy